Bringing Precision To Solid Tumor Targets
Insights From Achilles CEO, Iraj Ali
Executive Summary
Achilles Therapeutics is betting that its clonal neoantigen-targeting T cell (cNeT) products, combined with an industrial scale advanced manufacturing capability and predictive bioinformatics platform, will have a transformational impact on patients with solid tumors and metastasized cancer.
You may also be interested in...
30 Rising Leaders In The Life Sciences
Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who made the cut.
Syncona Biotechs Face Up To Trial Delays Over COVID-19
Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.
Carving Out New Spaces In Cancer Immunotherapy
With a combined $335m raised in a crossover series B funding and an IPO last summer, Cambridge, MA-based iTeos Therapeutics has the juice to move its two cancer immunotherapy clinical programs forward.
Need a specific report? 1000+ reports available
Buy Reports